6月的港股创新药市场再掀波澜——继核药龙头先通医药递交上市申请后,专注于多肽领域的CRDMO企业泰德医药于6月20日正式开启招股,预计6月30日登陆港交所主板。这家全球第三大多肽CRDMO企业的IPO进程,不仅标志着中国医药外包产业在细分领域的突破,更折射出多肽药物黄金赛道的资本热度。全球第三的商业版图2001年成立于杭州的中肽生化,如今已蜕变成为泰德医药的核心业务载体。这家总部位于中国、国际...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.